Enanta Pharmaceuticals, Inc.
330 articles about Enanta Pharmaceuticals, Inc.
-
Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
5/8/2023
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced topline data from SPRINT (SARS-Cov-2 PRotease INhibitor Treatment), a double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, Enanta’s oral, 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.
-
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
5/8/2023
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, reported financial results for its fiscal second quarter ended March 31, 2023.
-
Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023
5/2/2023
Enanta Pharmaceuticals, Inc. announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2023 after the U.S. market closes on May 8, 2023.
-
Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million
4/25/2023
Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET ® (U.S.)/MAVIRET ® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million.
-
Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases
4/17/2023
Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases.
-
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
4/6/2023
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDP-323, Enanta’s L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV).
-
Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
4/5/2023
Enanta Pharmaceuticals, Inc. announced that data for EDP-235, its lead 3CL protease inhibitor specifically designed as an oral, once-daily treatment for COVID-19, and EDP-323, its L-protein inhibitor in development for the treatment of respiratory syncytial virus, will be presented at the 33rd European Congress of Clinical Microbiology and Infectious Diseases being held April 15-18 both virtually and at the Bella Center Copenhagen in Copenhagen, Denmark.
-
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
3/8/2023
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research.
-
Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
3/7/2023
Enanta Pharmaceuticals, Inc . today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 10:00 a.m. ET.
-
Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
2/7/2023
Enanta Pharmaceuticals, Inc. today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 8:40 a.m. ET.
-
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET
2/7/2023
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal first quarter ended December 31, 2022.
-
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022
1/31/2023
Enanta Pharmaceuticals, Inc . today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2022 after the U.S. market closes on February 7, 2023.
-
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference
1/6/2023
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference.
-
Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Enanta Pharmaceuticals, Inc. today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 at 3:00 p.m. PT.
-
Enanta Pharmaceuticals to Participate in Two Investor Conferences in November
11/22/2022
Enanta Pharmaceuticals, Inc. today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in November.
-
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
11/21/2022
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2022.
-
Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022
11/14/2022
Enanta Pharmaceuticals, Inc. today announced that it plans to report its financial results for its fiscal fourth quarter and full year ended September 30, 2022 after the U.S. market closes on November 21, 2022.
-
Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19
11/9/2022
Enanta Pharmaceuticals, Inc. today announced the initiation of SPRINT(SARS-Cov-2 PRotease INhibitor Treatment), a Phase 2 clinical trial of EDP-235, Enanta’s lead oral, 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19.
-
Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022
10/19/2022
Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek ™ 2022.
-
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus
10/17/2022
Enanta Pharmaceuticals, Inc today announced that it has dosed the first subject in its Phase 1 clinical trial of EDP-323, a novel, oral L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV).